Search Results

Capricor Therapeutics announced that the Company is set to join the Russell 2000® Index and the broad-market Russell 3000® Index, effective at the open of U.S. equity markets, July 1, 2024.

July 1, 2024

·

5 min read

Biotech Beach

Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy

Capricor Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has scheduled a Pre-BLA (Biologics License Application) meeting with the Company in the third quarter of 2024 for deramiocel (CAP-1002), for the treatment of Duchenne Muscular Dystrophy (DMD).

June 25, 2024

·

5 min read

Biotech Beach

Capricor Therapeutics to Present at Upcoming Scientific and Medical Conferences

Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is scheduled to present at various upcoming scientific and medical conferences.

May 8, 2024

·

4 min read

Biotech Beach

Capricor Therapeutics to Present at Upcoming Investor Conferences

Capricor Therapeutics diseases, today announced that the Company is scheduled to present at two upcoming investor conferences.

March 21, 2024

·

4 min read

Press Releases

Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

January 2, 2025

·

7 min read